Stock Scorecard

Stock Summary for Arcutis Biotherapeutics Inc (ARQT) - $13.25 as of 6/6/2025 7:05:36 PM EST

Total Score

7 out of 30

Safety Score

33 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for ARQT

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for ARQT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for ARQT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for ARQT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for ARQT (33 out of 100)

Stock Price Rating (Max of 10) 5
Historical Stock Price Rating (Max of 10) 7
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 2
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for ARQT

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) - Arcutis Biotherapeutics ( NASDAQ:ARQT ) 6/6/2025 8:00:00 PM
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 6/6/2025 8:00:00 PM
Arcutis Unveils Long-Term Efficacy, Safety For Zoryve Cream In Pediatric Patients With Atopic Dermatitis - Arcutis Biotherapeutics ( NASDAQ:ARQT ) 6/6/2025 3:11:00 PM
Arcutis' ZORYVE® ( roflumilast ) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - Arcutis Biotherapeutics ( NASDAQ:ARQT ) 5/22/2025 6:12:00 PM
Arcutis' ZORYVE® ( roflumilast ) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older 5/22/2025 6:12:00 PM
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - Arcutis Biotherapeutics ( NASDAQ:ARQT ) 5/15/2025 1:29:00 PM
New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice 5/15/2025 1:29:00 PM
Arcutis Announces Publication of Positive Data from ARRECTOR Trial Evaluating ZORYVE® ( roflumilast ) Foam 0.3% in Individuals with Psoriasis in Journal of American Medical Association Dermatology 5/7/2025 3:18:00 PM
Arcutis Biotherapeutics, Inc. ( ARQT ) Reports Q1 Loss, Tops Revenue Estimates 5/6/2025 9:10:00 PM
Phathom Pharmaceuticals, Inc. ( PHAT ) Reports Q1 Loss, Tops Revenue Estimates 5/1/2025 12:15:00 PM

Financial Details for ARQT

Company Overview
Ticker ARQT
Company Name Arcutis Biotherapeutics Inc
Country USA
Description Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company is headquartered in Westlake Village, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 3/31/2025
Next Earnings Date N/A

Stock Price History
Last Day Price 13.25
Price 4 Years Ago 20.74
Last Day Price Updated 6/6/2025 7:05:36 PM EST
Last Day Volume 1,332,440
Average Daily Volume 1,957,542
52-Week High 17.75
52-Week Low 6.99
Last Price to 52 Week Low 89.56%

Valuation Measures
Trailing PE N/A
Industry PE 22.42
Sector PE 40.76
5-Year Average PE -19.73
Free Cash Flow Ratio 29.44
Industry Free Cash Flow Ratio 17.42
Sector Free Cash Flow Ratio 31.56
Current Ratio Most Recent Quarter 3.55
Total Cash Per Share 0.45
Book Value Per Share Most Recent Quarter 1.20
Price to Book Ratio 11.29
Industry Price to Book Ratio 34.35
Sector Price to Book Ratio 29.98
Price to Sales Ratio Twelve Trailing Months 7.57
Industry Price to Sales Ratio Twelve Trailing Months 149.68
Sector Price to Sales Ratio Twelve Trailing Months 40.34
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 3

Share Statistics
Total Shares Outstanding 119,202,000
Market Capitalization 1,579,426,500
Institutional Ownership N/A

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth 46.58%
Reported EPS 12 Trailing Months -1.04
Reported EPS Past Year -0.20
Reported EPS Prior Year -1.16
Net Income Twelve Trailing Months -129,717,000
Net Income Past Year -140,039,000
Net Income Prior Year -262,140,000
Quarterly Revenue Growth YOY 32.80%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months -37.20%

Balance Sheet
Total Cash Most Recent Quarter 53,104,000
Total Cash Past Year 71,335,000
Total Cash Prior Year 88,398,000
Net Cash Position Most Recent Quarter -54,514,000
Net Cash Position Past Year -35,868,000
Long Term Debt Past Year 107,203,000
Long Term Debt Prior Year 201,799,000
Total Debt Most Recent Quarter 107,618,000
Equity to Debt Ratio Past Year 0.60
Equity to Debt Ratio Most Recent Quarter 0.57
Total Stockholder Equity Past Year 157,541,000
Total Stockholder Equity Prior Year 88,667,000
Total Stockholder Equity Most Recent Quarter 142,658,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months -116,686,000
Free Cash Flow Per Share Twelve Trailing Months -0.98
Free Cash Flow Past Year -112,301,000
Free Cash Flow Prior Year -247,485,000

Options
Put/Call Ratio 0.12
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD -0.24
MACD Signal -0.17
20-Day Bollinger Lower Band 11.54
20-Day Bollinger Middle Band 13.93
20-Day Bollinger Upper Band 16.32
Beta 1.78
RSI 43.78
50-Day SMA 11.92
150-Day SMA 11.61
200-Day SMA 13.62

System
Modified 6/6/2025 5:46:58 PM EST